Results 251 to 260 of about 31,417,423 (292)
Some of the next articles are maybe not open access.
Physiologically based pharmacokinetic modelling
2003AbstractThis chapter provides a general introduction to physiologically based pharmacokinetic (PBPK) modeling of exposure in occupational and environmental epidemiological studies. It describes models that could be used for the assessment. It provides various examples and references.
George Loizou, Martin Spendiff
openaire +1 more source
Physiologically-Based Pharmacokinetic Modeling and Bioactivation of Xenobiotics
Toxicology and Industrial Health, 1994This paper describes the development and implementation of physiologically-based pharmacokinetic (PB-Pk) models to examine the disposition of xenobiotics and their bioactivation. In a PB-Pk model, the structure of the model is based, to as great extent as practicable, on the actual physiological and biochemical structure of the animal system being ...
H J, Clewell, M E, Andersen
openaire +2 more sources
Development of a physiologically based pharmacokinetic model for chloroform
Toxicology and Applied Pharmacology, 1990A physiologically based pharmacokinetic model describing the disposition of chloroform in mice, rats, and humans was developed. This model was designed to facilitate extrapolations from high doses, such as those used in chronic rodent studies, to low doses that humans may be exposed to in the workplace or the environment. Kinetic constants for mice and
R A, Corley +7 more
openaire +2 more sources
Physiologically-Based Pharmacokinetic Modeling
Drug Information Journal, 1994Physiologically-based pharmacokinetic (PB-PK) models attempt to provide both a realistic anatomic description of the animal to which a drug or toxic chemical has been administered and a biologically accurate representation of the physiological pathways for chemical storage, metabolism, and elimination in the animal.
openaire +1 more source
Development of a Physiologically Based Pharmacokinetic Model for Hydroquinone
Toxicology and Applied Pharmacology, 2000Hydroquinone (HQ) produces nephrotoxicity and renal tubular adenomas in male F344 rats following 2 years of oral dosing. Female F344 and SD rats are comparatively resistant to these effects. Nephrotoxicity and tumorigenicity have been associated with a minor glutathione conjugation pathway following the oxidation of HQ to benzoquinone (BQ).
R A, Corley +4 more
openaire +2 more sources
Structural Identifiability of Physiologically Based Pharmacokinetic Models
Journal of Pharmacokinetics and Pharmacodynamics, 2006When starting a project in drug kinetics it is necessary to test a priori whether there is sufficient information in the experimental input-output design to estimate unique values of internal rate constants. This is an important test if the pharmacokinetics of a drug are to be characterised in some way by the parameter values estimated from the ...
openaire +2 more sources
Physiologically Based Pharmacokinetic Modeling: Principles and Applications
Journal of Pharmaceutical Sciences, 1983Concentrations of bromophenol blue (I) in plasma, urine, and bile were determined spectrophotometrically after intravenous bolus injections and infusions in rats. The plasma concentrations were found to decrease monoexponentially after all doses except the highest, where the decrease was biexponential.
L E, Gerlowski, R K, Jain
openaire +2 more sources
Whole-body physiologically based pharmacokinetic models
Expert Opinion on Drug Metabolism & Toxicology, 2007This review summarizes the most recent developments in and applications of physiologically based pharmacokinetic (PBPK) modeling methodology originating from both the pharmaceutical and environmental toxicology areas. It focuses on works published in the last 5 years, although older seminal papers have also been referenced.
openaire +2 more sources
Physiologically based pharmacokinetic models for anticancer drugs
Cancer Chemotherapy and Pharmacology, 1979The rationale and history of the development of physiologically based pharmacokinetic models are briefly reviewed in this paper. The methods of model construction and the previous application of this type of model to anticancer drugs are discussed. Future research should be focused on the following areas: (1) interspecies scaling, (2) the effects of ...
H S, Chen, J F, Gross
openaire +2 more sources
Physiology-based pharmacokinetic modeling: ready to be used
Drug Discovery Today: Technologies, 2004Physiology-based pharmacokinetic (PBPK) modeling is well recognized as a technology for mechanistically simulating and predicting the fate of substances in a mammalian body. Today, the demand for this methodology is higher than ever. The pharma industry and regulatory agencies are looking for new methods, which help to speed up and increase the ...
Walter, Schmitt, Stefan, Willmann
openaire +3 more sources